Caitong International Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Caitong International Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.8K	Sell	553 -2,512	-82%	-$45.5K	﹤0.01%	1141
2026 Q1	$57.1K	Sell	3,065 -3,885	-56%	-$64.4K	0.01%	740
2025 Q4	$91.6K	Sell	6,950 -77,603	-92%	-$916K	0.02%	462
2025 Q3	$606K	Buy	84,553 +84,177	+22,388%	+$4.39M	0.42%	26
2025 Q2	$17.7K	Buy	376 +229	+156%	+$9.33K	0.01%	534
2025 Q1	$5.74K	Buy	+147	New	+$6.33K	﹤0.01%	987

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caitong International Asset Management's MLTX Position: Q2 2026 in Review

Caitong International Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 82% in Q2 2026, selling an estimated $45.5K and leaving 553 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Caitong International Asset Management first reported a position in MLTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $606K in Q3 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Caitong International Asset Management held 553 shares of MoonLake Immunotherapeutics worth $10.8K as of Q2 2026.
Caitong International Asset Management sold 2,512 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $45.5K.
MoonLake Immunotherapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1141 holding.
Caitong International Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 6 quarters since.
Caitong International Asset Management's MoonLake Immunotherapeutics position peaked at $606K in Q3 2025.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.